English
ホーム > 研究成果

研究成果

計画班

【畠山班】

  • *Hatakeyama M. Helicobacter pylori CagA and gastric cancer: A paradigm for Hit-and-Run Carcinogenesis. Cell Host Microbe 15, 306-316, 2014.
  • Hashi K, *Murata-Kamiya N, Varon C, Megraud F, Domiguez-Bello MG and Hatakeyama M. A natural variant of the Helicobacter pylori CagA oncoprotein that lost the ability to interact with PAR1. Cancer Sci 105, 245-251, 2014.
  • *Bessède E, Staedel C, Acuña Amador LA, Nguyen PH, Chambonnier L, Hatakeyama M, Belleannée G, Mégraud F and Varon C. Helicobacter pylori generates cells with cancer stem cell properties via epithelial-mesenchymal transition-like changes. Oncogene, 33, 4123-4131, 2013.
  • Tsutsumi R, Masoudi M, Takahashi A, Fujii Y, Hayashi T, Kikuchi I, Satou Y, Taira M and *Hatakeyama M. YAP and TAZ, Hippo signaling targets, act as a rheostat for nuclear SHP2 function. Dev Cell 26, 658-665, 2013.
  • *Miura K, Wakayama Y, Tanino M, Orba Y, Sawa H, Hatakeyama M, Tanaka S, Sabe H and Mochizuki N. Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular signal-regulated kinase. Oncogene 32, 5292-5301.
  • Hayashi T, Morohashi H and *Hatakeyama M. Bacterial EPIYA effectors – Where do they come from? What are tey? Where are they going? Cell Microbiol 15, 377-385, 2013.
  • Yamahashi Y and *Hatakeyama M. PAR1b takes the stage in the morphogenetic and motogenetic activity of Helicobacter pylori CagA oncoprotein. Cell Adh Migr 7, 11-17, 2013.
  • Tsugawa H, *Suzuki H, Seya H, Hatakeyama M, Hirayama T, Hirata K, Nagano O, Matsuzaki J and Hibi T. Reactive oxygen species-induced autophagic degradation of Helicobacter pylori CagA is specifically suppressed in cancer stem-like cells. Cell Host Microbe 12, 764-777, 2012.
  • Fujii Y, Yoshihashi K, Suzuki H, Tsutsumi S, Mutoh H, Maeda S, Yamagata Y, Seto Y, Aburatani H and *Hatakeyama M. CDX1 confers intestinal phenotype on gastric epithelial cells via induction of stemnes-associated reprogramming factors SALL4 and KLF5. Proc Natl Acad Sci USA 109, 20584-20589, 2012.
  • Hayashi T, Senda M, Morohashi H, Higashi H, Horio M, Kashiba Y, Nagase L, Sasaya D, Shimizu T, Venugopalan N, Kumeta H, Noda NN, Inagaki F, Senda T and *Hatakeyama M. Tertiary structure-function analysis reveals the pathogenic signaling potentiation mechanism of Helicobacter pylori oncogenic effector CagA. Cell Host Microbe 12, 20-33, 2012.
  • Lee KS, Kalantzis A, Jackson CB, O'Connor L, Murata-Kamiya N, Hatakeyama M, Judd LM, Giraud AS and *Menheniott TR. Helicobacter pylori CagA Triggers Expression of the Bactericidal Lectin REG3γ via Gastric STAT3 Activation. PLoS One 7, e30786, 2012.
  • Kikuchi K, Murata-Kamiya N, Kondo S and *Hatakeyama M. Helicobacter pylori stimulates epithelial cell migration via CagA-mediated perturbation of host cell signaling. Microbes Infect 14, 470-476, 2012.
  • Yamahashi Y, Saito Y, Murata-Kamiya N and *Hatakeyama M. Polarity-regulating kinase partitioning-defective 1b (PAR1b) phosphorylates guanine nucleotide exchange factor H1 (GEF-H1) to regulate RhoA-dependent actin cytoskeletal reorganization. J Biol Chem 286, 44576-44584, 2011.
  • Safari F, Murata-Kamiya N, Saito Y and *Hatakeyama M. Mammalian Pragmin regulates Src family kinases via the Glu-Pro-Ile-Tyr-Ala (EPIYA) motif that is exploited by bacterial effectors. Proc Natl Acad Sci USA 108, 14938-14943, 2011.
  • Furuta Y, Yahara K, Hatakeyama M and *Kobayashi I. Evolution of cagA Oncogene of Helicobacter pylori through recombination. PLoS One 6, e23499, 2011.
  • Nagase L, Murata-Kamiya N and *Hatakeyama M. Potentiation of Helicobacter pylori CagA virulence through homodimerization. J Biol Chem 286, 33622-33631, 2011.
  • Takahashi A, Tsutsumi R, Kikuchi I, Obuse C, Saito Y, Seidi A, Karisch R, Fernandez M, Cho T, Ohnishi N, Rozenblatt-Rosen O, Meyerson M, Neel BG and *Hatakeyama M. SHP2 Tyrosine phosphatase converts Parafibromin/Cdc73 from a tumor suppressor to an oncogenic driver. Mol Cell 43, 45-56, 2011.
  • *Hatakeyama M. Anthropological and clinical implications for the structural diversity of the Helicobacter pylori CagA oncoprotein. Cancer Sci 102, 36-43, 2011.
  • Saito Y, Murata-Kamiya N, Hirayama T, Ohba Y and *Hatakeyama M. Conversion of Helicobacter pylori CagA from senescence inducer to oncogenic driver through polarity-dependent regulation of p21. J Exp Med 207, 2157-2174, 2010.
  • Murata-Kamiya N, Kikuchi K, Hayashi T, Higashi H and *Hatakeyama M. Helicobacter pylori exploits host membrane phosphatidylserine for delivery, localization, and pathophysiological action of the CagA oncoprotein. Cell Host Microbe 7, 399-411, 2010.
  • *Ding SZ, Goldberg JB and Hatakeyama M. Helicobacter pylori infection, oncogenic pathways and epigenetic mechanisms in gastric carcinogenesis. Future Oncol 6, 851-862, 2010.
  • Ding SZ, Fischer W, Kaparakis-Liaskos M, Liechti G, Merrell DS, Grant PA, Ferrero RL, Crowe SE, Haas R, Hatakeyama M and *Goldberg JB. Helicobacter pylori-induced histone modification, associated gene expression in gastric epithelial cells, and its implication in pathogenesis. PLoS One 1, e9875, 2010.
  • Tanaka H, *Yoshida M, Nishiumi S, Ohnishi N, Kobayashi K, Yamamoto K, Fujita T, Hatakeyama M and Azuma T. The CagA protein of Helicobacter pylori suppresses the functions of dendritic cell in mice. Arch Biochem Biophys 498, 35-42, 2010.

このページの先頭へ

【松岡班】

  • Cook LB, Melamed A, Niederer H, Valganon M, Laydon D, Foroni L, Taylor GP, Matsuoka M, *Bangham CR. The role of HTLV-1 clonality, proviral structure and genomic integration site in adult T cell leukemia/lymphoma. Blood, 123: 3925-3931, 2014.
  • *Furuta RA, Ma G, Matsuoka M, Otani S, Matsukura H, Hirayama F. Re-evaluation of screening of plasma positive for human T-cell leukemia virus type 1 using a luciferase immunoprecipitation system in blood donors. Transfusion, in press
  • *Zhao T, Satou Y and Matsuoka M. Development of T cell lymphoma in HTLV-1 bZIP factor and Tax double transgenic mice. Arch Virol, 159: 1849-1856, 2014.
  • Tanaka-Nakanishi A, Yasunaga J, Takai K, *Matsuoka M. HTLV-1 bZIP Factor Suppresses Apoptosis by Attenuating the Function of FoxO3a and Altering Its Localization. Cancer Res, 74; 188-200, 2014.
  • Azuma Y, Kükenshöner T, Ma G, Yasunaga J, Imanishi M, Tanaka G, Nakase I, Maruno T, Kobayashi Y, Arndt KM, Matsuoka M, *Futaki S. Controlling leucine-zipper partner recognition in cells through modification of a-g interactions. Chem Commun (Camb), 50; 6364-6367, 2014.
  • Zhao T, Coutts A, Xu L, Yu J, Ohshima K, Matsuoka M. HTLV-1 bZIP factor supports proliferation of adult T cell leukemia cells through suppression of C/EBP signaling. Retrovirology,10:159, 2013.
  • Miura M, Yasunaga J-I, Tanabe J, Sugata K, Zhao T, Ma G, Miyazato P, Ohshima K, Kaneko A, Watanabe A, Saito A, Akari H and Matsuoka M. Characterization of simian T-cell leukemia virus type 1 in naturally infected Japanese macaques as a model of HTLV-1 infection. Retrovirology, 10: 118, 2013.
  • Yamamoto-Taguchi N, Satou Y, Miyazato P, Ohshima K, Nakagawa M, Katagiri K, Kinashi T, and *Matsuoka M. HTLV-1 bZIP factor induces inflammation through labile Foxp3 expression. PLoS Pathogens, 9: e1003630, 2013.
  • Ma G, *Yasunaga J-I, Fan J, Yanagawa S-I, Matsuoka M. HTLV-1 bZIP factor dysregulates the Wnt pathways to support proliferation and migration of adult T-cell leukemia cells. Oncogene 32: 4222-4230, 2013.
  • *Matsuoka M and Yasunaga J-I. Human T-cell leukemia virus type 1: replication, proliferation and propagation by Tax and HTLV-1 bZIP factor. Curr Opin Virol, 3: 1-8, 2013.
  • *Satou Y and *Matsuoka M. Virological and immunogical mechanisms in the pathogenesis of human T-cell leukemia virus type 1. Rev Med Virol, 23: 269-280 2013.
  • Fujii M and Matsuoka M. Human T-cell leukemia virus type 1 and 2. Fields Virology, 6ht edition, Lippincott Williams & Wilkins, p1474-1501, 2013. (査読無)
  • Satou Y, Utsunomiya A, Tanabe J, Nakagawa M, Nosaka K, *Matsuoka M. HTLV-1 modulates the frequency and phenotype of FoxP3+CD4+ T cells in HTLV-1 infected individuals. Retrovirology 9: 46, 2012.
  • Zhao T, and *Matsuoka M. HBZ and its roles in HTLV-1 oncogenesis. Front. Microbiol, 3: 247, 2012.
  • Gazon H, Lemasson I, Polakowski N, Césaire R, Matsuoka M, Barbeau B, Mesnard JM, *Peloponese JM Jr. Human T-cell leukemia virus type 1 (HTLV-1) bZIP factor requires cellular transcription factor JunD to upregulate HTLV-1 antisense transcription from the 3' LTR. J Virol, 86: 9070-9078, 2012.
  • Douceron E, Kaidarova Z, Miyazato P, Matsuoka M, Murphy EL, *Mahieux R. HTLV-2 APH-2 expression is correlated with proviral load but APH-2 does not promote lymphocytosis. J Infect Dis, 205: 82-6, 2012.
  • Kiyasu J, Aoki R, Tanaka PY, Pracchia LF, Calore EE, Perez NM, Kimura Y, Niino D, Sugita Y, Takayanagi R, Abe Y, Matsuoka M, *Ohshima K. FOXP3(+) regulatory and TIA-1(+) cytotoxic T lymphocytes in HIV-associated Hodgkin lymphoma. Pathol Int. 62(2):77-83, 2012.
  • Sugata K, Satou Y, Yasunaga JI, Hara H, Ohshima K, Utsunomiya A, Mitsuyama M, *Matsuoka M. HTLV-1 bZIP factor impairs cell-mediated immunity by suppressing production of Th1 cytokines. Blood 119(2):434-444, 2011.
  • *Yasunaga J and Matsuoka M. Molecular mechanisms of HTLV-1 infection and pathogenesis. Int. J. Hematol 94; 435-442, 2011.
  • Zhao T, Satou Y, Sugata K, Miyazato P, Green PL, Imamura T, *Matsuoka M. HTLV-1 bZIP factor enhances TGF-β signaling through p300 coactivator. Blood 118; 1865-1876, 2011.
  • Shimizu-Kohno K, Satou Y, Arakawa F, Kiyasu J, Kimura Y, Niino D, Sugita Y, Ishikawa F, Matsuoka M, *Ohshima K. Detection of HTLV-1 by means of HBZ gene in situ hybridization in formalin-fixed and paraffin-embedded tissues. Cancer Sci 102; 1432-1436, 2011.
  • Hagiya K, Yasunaga JI, Satou Y, Oshima K, *Matsuoka M. ATF3, an HTLV-1 bZip factor binding protein, promotes proliferation of adult T-cell leukemia cells. Retrovirology 8; 19, 2011.
  • Satou Y, Yasunaga J, Zhao T, Yoshida M, Miyazato P, Takai K, Shimizu K, Ohshima K, Green PL, Ohkura N, Yamaguchi T, Ono M, Sakaguchi S, *Matsuoka M., while ociated myelopathy (HAM)uding HTLV-1 associated myelopathy (HAM/TSP) HTLV-1 bZIP factor induces T-cell lymphoma and systemic inflammation in vivo. PLoS Pathog 7:e1001274, 2011.
  • Matsuoka M and *Jeang KT. Human T cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ, and therapy. Oncogene 30:1379-1389,2011.
  • Sato K, Misawa N, Nie C, Satou Y, Iwakiri D, Matsuoka M, Takahashi R, Kuzushima K, Ito M, Takada K, *Koyanagi Y. A novel animal model of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in humanized mice. Blood 117: 5663-5673, 2011.
  • Fan J, Ma G, Nosaka K, Tanabe J, Satou Y, Koito A, Wain-Hobson S, Vartanian JP, *Matsuoka M. APOBEC3G generates nonsense mutations in HTLV-1 proviral genomes in vivo. J Virol 84: 7278-7287, 2010.
  • *Sato H, Oka T, Shinnou Y, Kondo T, Washio K, Takano M, Takata K, Morito T, Huang X, Tamura M, Kitamura Y, Ohara N, Ouchida M, Ohshima K, Shimizu K, Tanimoto M, Takahashi K, Matsuoka M, Utsunomiya A, Yoshino T. Multi-step aberrant CpG island hyper-methylation is associated with the progression of adult T–cell leukemia/lymphoma (ATLL). Am J Pathol 176: 402-415, 2010.
  • *Matsuoka M. HTLV-1 bZIP factor gene: its roles in HTLV-1 pathogenesis. Molecular Aspects of Medicine, 31: 359-66, 2010.

このページの先頭へ

【下遠野班】

  • *Shimizu Y, Nishitsuji H, Marusawa H, Ujino S, Takaku H, *Shimotohno K.
  • The RNA-editing Enzyme APOBEC1 Requires Heterogeneous Nuclear Ribonucleoprotein Q Isoform 6 for Efficient Interaction with Interleukin-8 mRNA. J Biol Chem. 289(38): 26226-26238. 2014.
  • *Nakai M, Seya T, Matsumoto M, Shimotohno K, Sakamoto N, Aly HH. The J6JFH1 strain of hepatitis C virus infects human B-cells with low replication efficacy. Viral Immunol. 27(6): 285-294. 2014.
  • Tsugawa Y, Kato H, Fujita T, Shimotohno K, *Hijikata M. Critical role of interferon-α constitutively produced in human hepatocytes in response to RNA virus infection. PLoS One. 9(2): e89869. 2014.
  • Abe Y, Aly HH, Hiraga N, Imamura M, Wakita T, Shimotohno K, Chayama K, *Hijikata M. Thromboxane A2 synthase inhibitors prevent production of infectious hepatitis C virus in mice with humanized livers. Gastroenterology. 145(3): 658-667. 2013.
  • Nishitsuji H, Funami K, Shimizu Y, Ujino S, Sugiyama K, Seya T, Takaku H, *Shimotohno K. Hepatitis C virus infection induces inflammatory cytokines and chemokines mediated by the cross talk between hepatocytes and stellate cells. J Virol. 87(14): 8169-8178. 2013.
  • Kuroki M, Ariumi Y, Hijikata M, Ikeda M, Dansako H, Wakita T, Shimotohno K, *Kato N. PML tumor suppressor protein is required for HCV production. Biochem Biophys Res Commun. 430(2):592-597. 2013.
  • Weng L, Tian X, Gao Y, Watashi K, Shimotohno K, Wakita T, Kohara M, *Toyoda T. Different mechanisms of hepatitis C virus RNA polymerase activation by cyclophilin A and B in vitro. Biochim Biophys Acta. 1820(12):1886-1892. 2012.
  • Hirata Y, Ikeda K, Sudoh M, Tokunaga Y, Suzuki A, Weng L, Ohta M, Tobita Y, Okano K, Ozeki K, Kawasaki K, Tsukuda T, Katsume A, Aoki Y, Umehara T, Sekiguchi S, Toyoda T, Shimotohno K, Soga T, Nishijima M, Taguchi R, *Kohara M. Self-enhancement of hepatitis C virus replication by promotion of specific sphingolipid biosynthesis. PLoS Pathog. 8(8):e1002860. 2012.
  • Shimizu Y, Hishiki T, Ujino S, Sugiyama K, Funami K, *Shimotohno K. Lipoprotein component associated with hepatitis C virus is essential for virus infectivity.Curr Opin Virol. 1(1): 19-26. 2012.
  • Weng L, Kohara M, Wakita T, Shimotohno K, *Toyoda T. Detergent-induced activation of the hepatitis C virus genotype 1b RNA polymerase. Gene. 496(2): 79-87. 2012.
  • Aly HH, Shimotohno K, Hijikata M, *Seya T. In vitro models for analysis of the hepatitis C virus life cycle. Microbiol Immunol. 56(1):1-9. 2012.
  • Ujino S, Nishitsuji H, Sugiyama R, Suzuki H, Hishiki T, Sugiyama K, Shimotohno K, *Takaku H. The interaction between human initiation factor eIF3 subunit c and heat-shock protein 90: a necessary factor for translation mediated by the hepatitis C virus internal ribosome entry site. Virus Res.163(1):390-395. 2012.
  • Aly HH, Oshiumi H, Shime H, Matsumoto M, Wakita T, Shimotohno K, *Seya T. Development of mouse hepatocyte lines permissive for hepatitis C virus (HCV).
  • PLoS One. 6(6):e21284. 2012.
  • Onomoto K, Morimoto S, Kawaguchi T, Toyoda H, Tanaka M, Kuroda M, Uno K, Kumada T, Matsuda F, Shimotohno K, Fujita T, *Murakami Y. Dysregulation of IFN system can lead to poor response to pegylated interferon and ribavirin therapy in chronic hepatitis C. PLoS One. 6(5):e19799. 2012.
  • Morohashi K, Sahara H, Watashi K, Iwabata K, Sunoki T, Kuramochi K, Takakusagi K, Miyashita H, Sato N, Tanabe A, Shimotohno K, Kobayashi S, Sakaguchi K, *Sugawara F. Cyclosporin A associated helicase-like protein facilitates the association of hepatitis C virus RNA polymerase with its cellular cyclophilin B. PLoS One. 6(4):e18285. 2011.
  • Murakami Y, Toyoda H, Tanaka M, Kuroda M, Harada Y, Matsuda F, Tajima A, Kosaka N, Ochiya T, *Shimotohno K. The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS One. 6(1):e16081. 2011.
  • Oshiumi H, Ikeda M, Matsumoto M, Watanabe A, Takeuchi O, Akira S, Kato N, Shimotohno K, *Seya T. Hepatitis C virus core protein abrogates the DDX3 function that enhances IPS-1-mediated IFN-beta induction. PLoS One. 5(12):e14258. 2011

このページの先頭へ

【大島班】

  • Ju X, Ishikawa T, Naka K, Ito K, Ito Y, and *Oshima M. Context-dependent activation of Wnt signaling by tumor suppressor RUNX3 in gastric cancer cells. Cancer Sci. 105: 418-424, 2014.
  • Oshima H, Ishikawa T, Yoshida GJ, Naoi K, Maeda Y, Naka K, Ju X, Yamada Y, Minamoto T, Mukaida N, Saya H, and *Oshima M. TNF-a/TNFR1 signaling promotes gastric tumorigenesis through induction of Noxo1 and Gna14 in tumor cells. Oncogene, 33: 3820-3829, 2014.
  • Han TS, Hur K, Xu, G, Choi B, Okugawa Y, Toiyama Y, Oshima H, Oshima M, Lee HJ, Kim VN, Chang AN, Goel A, *Yang HK. MicroRNA-29c mediates initiation of gastric carcinogenesis by directly targeting ITGB1. Gut, in press
  • Oshima H, and *Oshima M. The role of PGE2-associated inflammatory responses in gastric cancer development. Semin Immunopathol, 35: 139-150, 2013.
  • Baird M, Ang PW, Clark I, Bishop D, Oshima M, Cook MC, Hemmings C, Takeishi S, Worthley D, Boussioutas A, Wang TC, and *Taupin D. The unfolded protein response is activated in Helicobacter-induced gastric carcinogenesis in a non-cell autonomous manner. Lab Invest, 93: 112-122, 2013.
  • Mohri T, Ueno M, Nagahama Y, Gong ZY, Asano M, Oshima H, Oshima M, Fujio Y, and *Takakura N. Requirement of SLD5 for early embryogenesis. PLos One, 8: e78961, 2013.
  • Oshima H, and *Oshima M. The inflammatory network in the gastrointestinal tumor microenvironment: lessons from mouse models. J Gastroenterol, 47: 97-106, 2012.
  • Kong D, Piao YS, Yamashita S, Oshima H, Oguma K, Fushida S, Fujimura T, Minamoto T, Seno H, Yamada Y, Satou K, Ushijima T, Ishikawa T, and *Oshima M. Inflammation-induced repression of tumor suppressor miR-7 in gastric tumor cells. Oncogene, 31: 3949-3960, 2012.
  • McCormack W, Oshima M, Tan P, and *Jenkins B. Toll-like receptor 2: therapeutic target for gastric garcinogenesis. Oncotarget, 3: 1260-1261, 2012.
  • Tye H, Kennedy CL, Najdovska M, McLeod L, McCormach W, Hughes N, Dev A, Sievert W, Ooi CH, Ishikawa TO, Oshima H, Bhathal PS, Parker A, Oshima M, Tan P, and *Jenkins B. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell, 22: 466-478, 2012.
  • Ohima Hs, Popivanova BK, Oguma K, Kong D, Ishikawa T, and *Oshima M. Activation of epidermal growth factor receptor signaling by the prostaglandin E2 receptor EP4 pathway during gastric tumorigenesis. Cancer Sci, 102: 713-719, 2011.
  • Oshima H, Hioki K, Popivanova BK, Oguma K, van Rooijen N, Ishikawa T, and *Oshima M. Prostaglandin E2 signaling and bacterial infection recruit tumor-promoting macrophages to mouse gastric tumors. Gastroenterology, 140: 596-607, 2011.
  • Sonoshita M, Aoki M, Fuwa H, Aoki K, Hosogi H, Sakai Y, Hashida H, Takabayashi A, Sasaki M, Robine S, Itoh K, Yoshioka K, Kakizaki F, Kitamura T, Oshima M, and *Taketo MM. Suppression of colon cancer metaplasia by Aes through inhibition of Notch signaling. Cancer Cell, 19: 125-137, 2011.
  • Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, Masuko T, Shimizu T, Ishikawa T, Kai K, Takahashi E, Imamura Y, Baba Y, Ohmura M, Suematsu M, Baba E, and *Saya H. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of xc- and thereby promotes tumor growth. Cancer Cell, 19: 387-400, 2011.
  • Kaneda A, Fujita T, Anai M, Yamamoto S, Nagae G, Morikawa M, Tsuji S, Oshima M, Miyazono K, and *Aburatani H. Activation of Bmp2-Smad1 signal and its regulation by coordinated alteration of H3K27 trimethylation in Ras-induced senescence. Plos Genetics, 7: e1002359, 2011.
  • Oshima H, and *Oshima M. Gastric tumor mouse models: Wnt activation and PGE2 induction. Pathology Int, 60: 599-607, 2010.
  • Oguma K, Oshima H, and *Oshima M. Inflammation, tumor necrosis factor and Wnt promotion in gastric cancer development. Future Oncology, 6: 515-526, 2010.
  • Ishimoto T, Oshima H, Oshima M, Kai K, Torii R, Masuko T, Baba H, *Saya H, and Nagano O. CD44(+) slow-cycling tumor cell expansion is triggered by cooperative actions of Wnt and Prostaglandin E2 in gastric tumorigenesis. Cancer Sci, 101: 673-678, 2010.

このページの先頭へ

【東班】

  • Yang L, Yamamoto K, Nishiumi S, Nakamura M, Matsui H, Takahashi S, Dohi T, Okada T, Kakimoto K, Hoshi N, *Yoshida M, Azuma T. Interferon-γ -producing B cells induce the formation of gastric lymphoid follicles after Helicobacter suis infection. Mucosal Immunol, in press
  • Yamamoto K, Nishiumi S, Yang L, Klimatcheva E, Pandina T, Takahashi S, Matsui H, Nakamura M, Zauderer M, *Yoshida M, Azuma T. Anti-CXCL13 antibody can inhibit the formation of gastric lymphoid follicles induced by Helicobacter infection. Mucosal Immunol, 7:44-1254, 2014.
  • Iwamoto A, *Tanahashi T, Okada R, Yoshida Y, Kikuchi K, Keida Y, Murakami Y, Yang L, Yamamoto K, Nishiumi S, Yoshida M, Azuma T. Whole-genome sequencing of clarithromycin resistant Helicobacter pylori characterizes unidentified variants of multidrug resistant efflux pump genes. Gut Pathog, 6:27, 2014.
  • Shimizu T, *Marusawa H, Matsumoto Y, Inuzuka T, Ikeda A, Fujii Y, Minamiguchi S, Miyamoto S, Kou T, Sakai Y, Crabtree JE, Chiba T. Accumulation of somatic mutations in TP53 in gastric epithelium with Helicobacter pylori infection. Gastroenterology, 147:407-417, 2014.
  • *Shimizu Y, Nishitsuji H, Marusawa H, Ujino S, Takaku H, Shimotohno K. The RNA-editing enzyme APOBEC1 requires heterogenous nuclear ribonucleoprotein Q isoform 6 for efficient interaction with interleukin-8 mRNA. J Biol Chem, 289:2626-2638, 2014.
  • *Nagata N, Akiyama J, Marusawa H, Shimbo T, Liu Y, Igari T, Nakashima R, Watanabe H, Uemura N, Chiba T. Enhanced expression of activation-induced cytidine deaminase in human gastric mucosa infected by Helicobacter pylori and its decrease following eradication. J Gastroenterol, 49:427-35, 2014.
  • Ikeda A, Shimizu T, Matsumoto Y, Fujii Y, Eso Y, Inuzuka T, Mizuguchi A, Shimizu K, Hatano E, Uemoto S, Chiba T, *Marusawa H. Leptin receptor somatic mutations are frequent in HCV-infected cirrhotic liver and associated with hepatocellular carcinoma. Gastroenterology, 146:222-232, 2014.
  • Lee M, Marusawa H, *Chiba T. Characteristics of hepatocellular carcinoma with stem/progenitor cell phenotypes. Gastroenterology, 146:579-581, 2014.
  • *Marusawa H, Jenkins BJ. Inflammation and gastrointestinal cancer: an overview. Cancer Lett, 345:153-156, 2014.
  • Kim SK, Nasu A, Komori J, Shimizu T, Matsumoto Y, Minaki Y, Kohno K, Shimizu K, Uemoto S, Chiba T, *Marusawa H. A model of liver carcinogenesis originating from hepatic progenitor cells with accumulation of genetic alterations. Int J Cancer, 134:1067-1076, 2014.
  • *Watashi K, Liang G, Iwamoto M, Marusawa H, Uchida N, Daito T, Kitamura K, Muramatsu M, Ohashi H, Kiyohara T, Suzuki R, Li J, Tong S, Tanaka Y, Murata K, Aizaki H, Wakita T. Interleukin-1 and tumor necrosis factor-a trigger restriction of hepatitis B virus infection via a cytidine deaminase activation-induced cytidine deaminase (AID). J Biol Chem, 288:31715-31727, 2013.
  • Kim SK, *Marusawa H, Eso Y, Chiba T, Kudo M. Novel mouse models of hepatocarcinogenesis with stepwise accumulation of genetic alterations. Dig Dis, 31:454-458, 2013.
  • *Yamada S, Kato S, Matsuhisa T, Makonkawkeyoon ., Yoshida M, Chakrabandhu T, Lertprasertsuk N, Suttharat P, Chakrabandhu B, Nishiumi S, Chongraksut W, Azuma T. Predominant mucosal IL-8 mRNA expression in non-cagA Thais is risk for gastric cancer. World J Gastroentrol, 19:2941-2949, 2013.
  • Yahara K, Furuta Y, Oshima K, Yoshida M, Azuma T, Hattori M, Uchiyama I, *Kobayashi I. Chromosome painting in silico in a bacterial species reveals fine population structure. Mol Biol Evol, 30:1454-1464, 2013.
  • Yahara K, Kawai M, Furuta Y, Takahashi N, Handa N, Tsuru T, Oshima K, Yoshida M, Azuma T, Hattori M, Uchiyama I, *Kobayashi I. Genome-wide survey of mutual homologous recombination in a highly sexual bacterial species. Genome Biol Evol, 4:628-640, 2012.
  • *Marusawa H, Endo Y, Takai A, Chiba T. Molecular mechanism of colitis-associated colorectal carcinogenesis. Inflamm Regen, 32: 67-71, 2012.
  • Takai A, *Marusawa H, Minaki Y, Watanabe T, Nakase H, Kinoshita K, Tsujimoto G, Chiba T. Targeting activation-induced cytidine deaminase prevents colon cancer development despite persistent colonic inflammation. Oncogene, 31: 1733-1742, 2012.
  • Takahashi K, Marusawa H, *Chiba T. Large-scale identification of effector genes that mediate the type I interferon antiviral response. Gastroenterology, 142: 178-180,2012.
  • Okuyama S, *Marusawa H, Matsumoto T, Ueda Y, Matsumoto Y, Endo Y, Takai A, Chiba T. Excessive activity of apolipoprotein B mRNA editing enzyme catalytic polypeptide 2 (APOBEC2) contributes to liver and lung tumorigenesis. Int J Cancer, 130: 1294-1301, 2012.
  • Shimizu T, Marusawa H, *Chiba T. Recurrent somatic mutations in human gastric cancers identified by whole exome sequencing.Gastroenterology, 143:1385-1387, 2012.
  • *Chiba T, Marusawa H, Ushijima T. Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology, 143:550-563, 2012.
  • Shimizu T, *Marusawa H, Endo Y, Chiba T. Inflammation-mediated genomic instability: roles of activation-induced cytidine deaminase in carcinogenesis. Cancer Sci, 103:1201-1206, 2012.
  • *Marusawa H, Takai A, Chiba T. Role of activation-induced cytidine deaminase in inflammation-associated cancer development. Adv Immunol, 111:109-141, 2011.
  • Takai A, *Marusawa H, Minaki Y, Watanabe T, Nakase H, Kinoshita K, Tsujimoto G, Chiba T. Targeting activation-induced cytidine deaminase prevents colon cancer development despite persistent colonic inflammation. Oncogene, 31:1733-1742, 2012.
  • Okuyama S, *Marusawa H, Matsumoto T, Ueda Y, Matsumoto Y, Endo Y, Takai A, Chiba T. Excessive activity of apolipoprotein B mRNA editing enzyme catalytic polypeptide 2 (APOBEC2) contributes to liver and lung tumorigenesis. Int J Cancer, 130:1294-1301, 2012.
  • *Marusawa H, Chiba T. A marker for domant cancer stem cells in human hepatocellular carcinoma. Gastroenterology, 140:1353-1355, 2011.
  • Takai A, *Marusawa H, Chiba T. Acquisition of genetic aberrations by activation-induced cytidine deaminase (AID) during inflammation-associated carcinogenesis. Cancers (Basel), 3:2750-2766, 2011.
  • Endo Y, *Marusawa H, Chiba T. Involvement of activation-induced cytidine deaminase in the development of colitis-associated colorectal cancers. J Gastroenterol, 46 (Suppl 1):6-10, 2011.
  • Kido M, Watanabe N, Aoki N, Iwamoto S, Nishiura H, Maruoka R, Ikeda A, Azuma T, *Chiba T. Dual oles of CagA protein in Helicobacter pylori-induced chronic gastritis in mice. Biochem Biophys Res Commun, 412:266-272, 2011.
  • Mimura T, Yoshida M, Nishiumi S, Tanaka H, Nobutani K, Takenaka M, Suleiman YB, Yamamoto K, Ota H, Takahashi S, Matsui H, Nakamura M, Miki I, *Azuma T. IFN-γ plays an essential role in the pathogenesis of gastric lymphoid follicles formation caused by Helicobacter suis infection. FEMS Immunol Med Microbiol, 63:25-34, 2011.
  • Kawai M, Furuta Y, Yahara K, Tsuru T, Oshima K, Handa N, Takahashi N, Yoshida M, Azuma T, Hattori M, Uchiyama I, *Kobayashi I. Evolution in an oncogenic bacterial species with extreme genome plasticity: Helicobacter pylori East Asian genomes. BMC Microbiol, 11:104, 2011.
  • Yamamoto K, Tanaka H, Nishitani Y, Nishiumi S, Miki I, Takenaka M, Nobutani K, Mimura T, Ben Suleiman Y, Mizuno S, Kawai M, Uchiyama I, Yoshida M, *Azuma T. Helicobacter suis KB1 derived from pig gastric lymphoid follicles induces the formation of gastric lymphoid follicles in mice through the activation of B cells and CD4 positive cells. Microbes Infect, 13:697-708, 2011.
  • Furuta Y, Kawai M, Yahara K, Takahashi N, Handa N, Tsuru T, Oshima K, Yoshida M, Azuma T, Hattori M, Uchiyama I, *Kobayashi I. Birth and death of genes linked to chromosomal inversion. Proc Natl Acad Sci U S A, 108:1501-1506, 2011.
  • *Marusawa H, Takai A, Chiba T. Role of activation-induced cytidine deaminase in inflammation-associated cancer development. Adv Immunol, 111: 109-141, 2011.
  • *Marusawa H, Chiba T. Helicobacter pylori-induced activation-induced cytidine deaminase expression and carcinogenesis. Curr Opin Immunol, 22:442-447, 2010.
  • Matsumoto Y, *Marusawa H, Kinoshita K, Niwa Y, Sakai Y, Chiba T. Up-regulation of activation-induced cytidine deaminase causes genetic aberrations at the CDKN2b-CDKN2a in gastric cancer. Gastroenterology, 139:1984-1994, 2010.
  • Nobutani K, Yoshida M, Nishiumi S, Nishitani Y, Takagawa T, Tanaka H, Yamamoto K, Mimura T, Bensuleiman Y, Ota H, Takahashi S, Matsui H, Nakamura M, *Azuma T. Helicobacter heilmannii can induce gastric lymphoid follicles in mice via a Peyer's patch-independent pathway. FEMS Immunol Med Microbiol, 60:156-164, 2010.
  • Cortes MC, Yamakawa A, Casingal CR, Fajardo LS, Juan ML, De Guzman BB, Bondoc EM; St. Luke's Helicobacter pylori Study Group, Mahachai V, Yamazaki Y, Yoshida M, Kutsumi H, Natividad FF, *Azuma T. Diversity of the cagA gene of Helicobacter pylori strains from patients with gastroduodenal diseases in the Philippines. FEMS Immunol Med Microbiol, 60:90-97, 2010.
  • Tanaka H, Yoshida M, Nishiumi S, Ohnishi N, Kobayashi K, Yamamoto K, Fujita T, Hatakeyama M, *Azuma T. The CagA protein of Helicobacter pylori suppresses the functions of dendritic cell in mice. Arch Biochem Biophys, 498:35-42, 2010.
  • *Mizuno S, Miki I, Ishida T, Yoshida M, Onoyama M, Azuma T, Habu Y, Inokuchi H, Ozasa K, Miki K, Watanabe Y. Prescreening of a high-risk group for gastric cancer by serologically determined Helicobacter pylori infection and atrophic gastritis. Dig Dis Sci, 55: 3132-3137, 2010.
  • Horie T, Ono K, Horiguchi M, Nishi H, Nakamura T, Nagao K, Kinoshita M, Kuwabara Y, Marusawa H, Iwanaga Y, Hasegawa K, Yokode M, Kimura T, *Kita T. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci USA, 107: 17321-17326, 2010.

このページの先頭へ

【谷口班】

  • Chiba S, Ikushima H, Ueki H, Yanai H, Kimura Y, Hangai S, Nishio J, Negishi H, Tamura T, Saijo S, Iwakura Y, *Taniguchi T.; Recognition of tumor cells by Dectin-1 orchestrates innate immune cells for anti-tumor responses. eLife 3: e04177, 2014.
  • Yanai H. and *Taniguchi T.; Nucleic acid sensing and beyond: Virtues and vices of HMGB1. J. Int. Med., in press 2014.
  • Yanai H, Matsuda A, An J, Koshiba R, Nishio J, Negishi H, Ikushima H, Onoe T, Ohdan H, Yoshida N. and *Taniguchi T.; Conditional ablation of HMGB1 in mice reveals its protective function against endotoxemia and bacterial infection. Proc. Natl. Acad. Sci. USA. 110: 20699-20704, 2013.
  • Negishi H, Matsuki K, Endo N, Sarashina H, Miki S, Matsuda A, Fukazawa K, Taguchi-Atarashi N, Ikushima H, Yanai H, Nishio J, Honda K, Fujioka Y, Ohba Y, Noda T, Taniguchi S, Nishida E, Zhang Y, Chi H, Flavell RA. and *Taniguchi T: Beneficial innate signaling interference for anti-bacterial responses by a TLR-mediated enhancement of the MKP-IRF3 axis. Proc. Natl. Acad. Sci. USA. 110: 19884-19889, 2013.
  • Ikushima H, Negishi H, and *Taniguchi T.; The IRF family transcription factors at the interface of innate and adaptive immune responses. Cold Spring Harbor Symposia on Quantitative Biology. 78: 105-116, 2013.
  • Atarashi K, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H, Fukuda S, Saito T, Narushima S, Hase K, Kim S, Fritz JV, Wilmes P, Ueha S, Matsushima K, Ohno H, Olle B, Sakaguchi S, Taniguchi T, Morita, H., Hattori, M., and *Honda, K.; Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 500: 232-236, 2013.
  • Koshiba R, Yanai H, Matsuda A, Goto A, Nakajima A, Negishi H, Nishio J, Smale ST, and *Taniguchi T.; Regulation of cooperative function of the Il12b enhancer and promoter by the interferon regulatory factors 3 and 5. Biochem. Biophys. Res. Commun. 430: 95-100, 2013.
  • Negishi H, Miki S, Sarashina H, Taguchi-Atarashi N, Nakajima A, Matsuki K, Endo N, Yanai H, Nishio J, Honda K and *Taniguchi T.; Essential contribution of IRF3 to intestinal homeostasis and microbiota-mediated Tslp gene induction. Proc. Natl. Acad. Sci. USA. 109: 21016-21021, 2012.
  • Yanai H, Negishi H, and *Taniguchi T.; The IRF family of transcription factors: Inception, impact and implications in oncogenesis. Oncoimmunol. 1: 1376-1386, 2012.
  • Yanai H, Ban T. and *Taniguchi T.; High-mobility group box family of proteins: ligand and sensor for innate immunity. Trends Immunol. 33: 633-640, 2012.
  • Negishi H, Yanai H, Nakajima A, Koshiba R, Atarashi K, Matsuda A, Matsuki K, Miki S, Doi T, Aderem A, Nishio J, Smale ST, Honda K and *Taniguchi T.; Cross-interference of RLR and TLR signaling pathways modulates antibacterial T cell responses. Nat. Immunol. 13: 659-666, 2012.
  • Idrus E, Nakashima T, Wang L, Hayashi M, Okamoto K, Kodama T, Tanaka N, Taniguchi T. and *Takayanagi H.; The role of the BH3-only protein Noxa in bone homeostasis. Biochem. Biophys. Res. Commun. 410: 620-625, 2011.
  • Yanai H, Chiba S, Ban T, Nakaima Y, Onoe T, Honda K, Ohdan H. and *Taniguchi T.; Suppression of immune responses by nonimmunogenic oligodeoxynucleotides with high affinity for high-mobility group box proteins (HMGBs). Proc. Natl. Acad. Sci. USA. 108: 11542-11547, 2011.
  • Yanai H, Ban T. and *Taniguchi T.; Essential role of high-mobility group proteins in nucleic acid-mediated innate immune responses. J. Intern. Med. 270: 301-308, 2011.
  • Savitsky D, Yanai H, Tamura T, *Taniguchi T. and Honda K;
Contribution of IRF5 in B cells to the development of murine SLE-like disease through its transcriptional control of the IgG2a locus.
 Proc. Natl. Acad. Sci. USA 107: 10154-10159, 2010.
  • Matsuda A, Ogawa M, Yanai H, Naka D, Goto A, Ao T, Tanno Y, Takeda K, Watanabe Y, Honda K, and *Taniguchi T.; Generation of mice deficient in RNA-binding motif protein 3 (RBM3) and characterization of its role in innate immune responses and cell growth. Biochem. Biophys. Res. Commun. 411: 7-13, 2011.
  • Tsushima K, Osawa T, Yanai H, Nakajima A, Takaoka A, Manabe I, Ohba Y, Imai Y, Taniguchi T., and *Nagai R.; IRF3 regulates cardiac fibrosis but not hypertrophy in mice during angiotensin Ⅱ-induced hypertension FASEB J. 25: 1531-1543, 2011.
  • Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, Cheng G, Yamasaki S, Saito T, Ohba Y, Taniguchi T, Takeda K, Hori S, Ivanov I, Umesaki Y, Itoh K. and *Honda K.; Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331: 337-341, 2011.
  • Ebihara T, Azuma M, Oshiumi H, Kasamatsu J, Iwabuchi K, Matsumoto K, Saito H, Taniguchi T, Matsumoto M, and *Seya T.; Identification of a polyI:C-inducible membrane protein, that participates in dendritic cell-mediated natural killer cell activation. J. Exp. Med. 207: 2675-2687, 2010.
  • Savitsky D, Tamura T, Yanai H. and *Taniguchi T.; Regulation of immunity and oncogenesis by the IRF transcription factor family. Cancer Immunol. Immunother. 59: 489-510, 2010.
  • Savitsky D, Yanai H, Tamura T, Taniguchi T. and *Honda K.;
Contribution of IRF5 in B cells to the development of murine SLE-like disease through its transcriptional control of the IgG2a locus.
 Proc. Natl. Acad. Sci. USA 107: 10154-10159, 2010.

このページの先頭へ

【瀬谷班】

  • Takaki H, Takeda M, Maino M, Kobayashi F, Ebihara T, Oshiumi H, Matsumoto M, Shingai M, and *Seya T. MAVS-dependent IRF3/7 bypass of interferon -induction restricts the response to measles infection in CD150Tg mouse bone marrow-derived dendritic cells. Molec. Immunol. 57: 100-110. 2014.
  • Shime H, Kojima A, Maruyama A, Saito Y, Oshiumi H, Matsumoto M, and *Seya T. Myeloid-derived suppressor cells exhibit NK cell-priming activity in response to polyI:C in tumor-bearing mice. J. Innate Immun. 6: 293-305. 2014.
  • Okamoto M, Oshiumi H, Azuma M, Matsumoto M, and *Seya T. IPS-1 is essential for type III IFN production by hepatocytes and dendritic cells in response to hepatitis C virus infection. J. Immunol. 192: 2770-2777. 2014.
  • Nakai M, *Seya T, Matsumoto M, Shimotohno K, Sakamoto N, and Aly HH. The J6JFH1 strain of hepatitis C virus (HCV) infects human B cells with low replication efficacy. Viral Immunol. 27: 285-294. 2014.
  • Leong CR, Azuma M, Okamoto M, Matsumoto M, Aly HH, Oshiumi H, and *Seya T. A MAVS/TICAM-1-independent IFN-inducing pathway contributes to regulation of HBV replication in the mouse hydrodynamic injection model. J. Innate Immun., in press 2014.
  • Kasamatsu J, Takahashi S, Azuma M, Matsumoto M, Teshima T, Takahashi A, Hirohashi Y, Torigoe T, Sato N, and *Seya T. PolyI:C and mouse surviving artificially embedding human 2B peptide induce a CD4+ T cell response to autologous surviving in HLA-A*2402 transgenic mice. Immunobiol., in press 2014.
  • Kumeta H, Sakakibara H, Enokizono Y, Ogura K, Horiuchi M, Matsumoto M, Seya T, and Inagaki F. The N-terminal domain of TIR domain-containing adaptor molecule-1, TICAM-1. J Biomol NMR. 58: 227-230. 2014.
  • Kasamatsu J, Azuma M, Ebihara T, Matsumoto Z, Oshiumi H, and *Seya T. Natural killer cell priming by INAM causes production of IFN- and Th1 immunity to induce antitumor activity in mice. J. Immunol., in press 2014.
  • Ishii N, Funami K, Tatematsu M, Seya T, and Matsumoto M. Endosomal localization of Toll-like receptor 8 confers distinctive proteolytic processing on human myeloid cells. J. Immunol., in press 2014.
  • Matsumoto M, Tatematsu M, Nishikawa F, Azuma M, Shime H, and *Seya T. Chemical synthesis of a TLR3-specific adjuvant that induces NK and cytotoxic T cell activation without robust cytokine production in vivo. Nat Commun. (revised resubmitted). 2014.
  • Segawa T, Hazeki K, Nigorikawa K, Morioka S, Guo Y, Takasuga S, Asanuma K, and Hazeki O. Inpp5e increases the Rab5 association and phosphatidylinositol 3-phosphate accumulation at the phagosome through an interaction with Rab20. Biochem J., in press 2014.
  • Nigorikawa K, Hazeki K, Guo Y, and Hazeki O. Involvement of class II phosphoinositide 3-kinase α-isoform in antigen-induced degranulation in RBL-2H3 cells. PLoS ONE., in press 2014.
  • Toscano F, Estornes Y, Virard F, Garcia-Cattaneo A, Pierrot A, Vanbervliet B, Bonnin M, Ciancanelli MJ, Zhang SY, Funami K, Seya T, Matsumoto M, Pin JJ, Casanova JL, Renno T, and Lebecque S. Cleaved/associated TLR3 represents the primary form of the signaling receptor. J Immunol. 190: 764-773. 2013.
  • Tatematsu M, Nishikawa F, Seya T, and Matsumoto M. Toll-like receptor 3 recognizes incomplete stem structures in single-stranded viral RNA. Nat Commun. 4: 1833. 2013.
  • Enokizono Y, Kumeta H, Funami K, Horiuchi M, Sarmiento J, Yamashita Z, Standley D, Matsumoto M, *Seya T, Inagaki F. Structures and interface mapping of the Toll/Interleukin-1 receptor-domain-containing adaptor molecules involved in interferon signaling. Proc Natl Acad Sci USA. 110: 19908-19913. 2013.
  • Oshiumi H, Miyashita M, Matsumoto M, and Seya.T. A distinct role of Riplet-mediated K63-linked polyubiquitination of the RIG-I repressor domain in human antiviral innate immune responses. PLoS Pathog. 9 (8): e1003533. 2013.
  • Nishitsuji H, Funami K, Shimizu Y, Ujino S, Sugiyama K, Seya T, Takaku H, and Shimotohno K. Hepatitis C virus infection induces inflammatory cytokines and chemokines mediated by the cross talk between hepatocytes and stellate cells. J Virol. 87: 8169-8178. 2013.
  • Tanaka Y, Suenaga T, Matsumoto M, Seya T, and H Arase. Herpesvirus 6 Glycoproteins B (gB), gH, gL and gQ are necessary and sufficient for cell-to-cell fusion. J. Virol. 87: 10900-10903. 2013.
  • Takaki H, Takeda M, Tahara M, Shingai M, Oshiumi H, Matsumoto M, and *Seya T. MyD88 pathway in murine CD4+ and plasmacytoid dendritic cells triggers interferon- production leading to protection against measles in a murine model. J. Immunol. 191: 4740-4747. 2013.
  • Suzuki T, Oshiumi H, Miyashita M, Aly HH, Matsumoto M, and Seya T. Cell type-specific subcellular localization of phospho-TBK1 in response to cytoplasmic viral DNA. PLoS ONE. 8(12): e83639. 2013.
  • Kodama K, Higashiyama M, Okami J, Tokunaga T, Fujiwara A, Nishiyama K, Akazawa T, and Seya T. A possible abscopal effect of post-radiation immunotherapy in two patients with metastatic lung tumors. Int. J. Conf. J. s13691. 2013.
  • Hazeki K, Uehara M, Nigorikawa K, and Hazeki O. PIKfyve regulates the endosomal localization of CpG oligodeoxynucleotides to elicit TLR9-dependent cellular responses. PLoS ONE. 8 (9): e73894.2013.
  • Abe Y, Fujii K, Nagata N, Takeuchi O, Akira S, Oshiumi H, Matsumoto M, Seya T, and Koike S. Toll-like receptor 3-mediated antivirus response is important for protection against poliovirus infection in poliovirus receptor transgenic mice. J. Virol. 86: 185-194. 2012.
  • Shime H, Matsumoto M, Oshiumi H, Tanaka S, Nakane A, Iwakura Y,Tahara H, Inoue N, and *Seya T. TLR3/TICAM-1 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc Natl Acad Sci USA. 109: 2066-2071. 2012.
  • Azuma M, Ebihara T, Oshiumi H, Matsumoto M, and *Seya T. Cross-presentation and antitumor CTL induced by soluble Ag + polyI:C largely depend on the TICAM-1 pathway in mouse CD11c+/CD8+ dendritic cells. OncoImmunol. 1: 581-594. 2012.
  • Naito AT, Sumida T, Nomura S, Liu ML, Higo T, Nakagawa A, Okada K, Sakai T, Hashimoto A, Hara Y, Shimizu I, Zhu W, Toko H, Katada A, Akazawa H, Oka T, Lee JK, Minamino T, Nagai T, Walsh K, Kikuchi A, Matsumoto M, Botto M, Shiojima I, Komuro I. Complement C1q activates canonical Wnt signaling and promotes aging-related phenotypes. Cell. 149: 1298-1313. 2012.
  • Yamazaki S, Maruyama A, Okada K, Matsumoto M, Morita A, and *Seya T. Dendritic cells from oral cavity induce Foxp3+ regulatory T cells upon antigen stimulation. PLoS ONE. 7(12): e51665. 2012.
  • Hazeki K, Nigorikawa K, Takaba Y, Segawa T, Nukuda A, Masuda A, Ishikawa Y, Takasuga S, and Hazeki O. Essential roles of PIKfyve and PTEN on phagosomal phosphatidylinositol 3-phosphate dynamics. FEBS Lett. 586: 4010-4015. 2012.
  • Nigorikawa K, Hazeki K, Kumazawa T, Itoh Y, Hoshi M, and Hazeki O. Class-IA phosphoinositide 3-kinase p110β triggers GPCR-induced superoxide production in p110γ-deficient murine neutrophils. J. Pharmacol. Sci. 120: 270-279. 2012.
  • Yabu M, Shime H, Hara H, Saito T, Matsumoto M, Seya T, Akazawa T, and Inoue N. IL-23-dependent and –independent enhancement pathway of IL-17A production by lactic acid. Int. Immunol. 23: 29-41.2011.
  • Takaki H, Watanabe Y, Shingai M, Oshiumi H, Matsumoto M, and *Seya T. Strain-to-strain difference of V protein of measles virus affects MDA5-mediated IFN--inducing potential. Molec. Immunol. 48: 497-504. 2011.
  • Watanabe A, Tatematsu M, Saeki K, Shibata S, Shime H, Yoshimura A, Obuse C, Seya T, and Matsumoto M. Raftlin is involved in the nucleocapture complex to induce poly(I:C)-mediated TLR3 activation. J. Biol. Chem. 86: 10702-10711. 2011.
  • Sawahata R, Shime H, Yamazaki S, Fujimoto Y, Fukase K, Akazawa T, Inoue N, Matsumoto M, and *Seya T. Failure of mycoplasmal lipoprotein MALP-2 to induce NK cell activation through dendritic cell TLR2. Microbes Infect. 13: 350-358. 2011.
  • Miyashita M, Oshiumi H, Matsumoto M, and Seya T. The SKI2-related helicase DDX60 is a novel antiviral factor promoting RIG-I-like receptor-mediated signaling. Molec. Cell. Biol. 31: 3802-3819. 2011.
  • Wakasa K, Shime H, Kurita-Taniguchi M, Matsumoto M, Imamura M, and *Seya T. Development of monoclonal antibodies that specifically interact with necrotic lymphoma cells. Microbiol. Immunol. 55: 373-377. 2011.
  • Ogawa T, Tsuji-Kawahara S, Yuasa T, Kinoshita S, Chikaishi T, Takamura S, Matsumura H, Seya T, Saga T, and Miyazawa M. Natural killer cells recognize Friend retrovirus infected erythroid progenitor cells through NKG2D-RAE-1 interactions in vivo. J. Virol. 85: 5423-5435. 2011.
  • Yamazaki S, Okada K, Maruyama A, Matsumoto M, and *Seya T. TLR2-dependent induction of IL-10 and Foxp3+CD25+CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo. PLoS ONE. 6 (4). e18833. 2011.
  • Aly HH, Oshiumi H, Matsumoto M, Shimotohno K, Wakita T, and *Seya T. Establishing mouse hepatoma cell lines permissive to human hepatitis C virus. PLoS ONE. 6 (6): e21284. 2011.
  • *Seya T. ADDENDUM to the paper published in MIMM by Takaki et al. Molec. Immunol. 48: 1589-1590. 2011.
  • Oshiumi H, Okamoto M, Fujii K, Kawanishi T, Matsumoto M, Koike S, and *Seya T. The TLR3-TICAM-1 pathway is mandatory for innate immune responses to poliovirus infection. J. Immunol. 187: 5320-5327. 2011.
  • Sancho-Shimizu V, Pérez de Diego R, Lorenzo L, Halwani R, Alangari A, Fabrega S, Cardon A, Maluenda J, Tatematsu M, Mahvelati F, Herman M, Ciancanelli M, Guo Y, Ghadiri A, Boucheriti S, Plancoulaine S, Picard C, Rosenberg F, Tardieu M, Lebon P, Jouanguy E, Seya T, Matsumoto M, Rezeai N, Chaussabel D, Puel A, Abel L, Zhang S-Y,Al-Muhsen S, and Casanova J-L. Human TRIF deficiency in otherwise healthy patients with herpes simplex encephalitis. J. Clin. Invest. 121: 4889-4902. 2011.
  • Itoh H, Watanabe A, Iwano K, Funami K, Seya T, and Matsumoto M. UNC93B1 physically associates with human TLR8 and regulates TLR8-mediated signaling. PLoS ONE. 6(12): e28500. 2011.
  • Hazeki K, Kametani Y, Murakami H, Uehara M, Nigorokawa K, Takasuga S, Sasaki T, Matsumoto M, Seya T, and Hazeki O. Phosphoinositide 3-kinase controls the intracellular localization of CpG to limit DNA-PKcs-dependent IL-10 production in macrophages. PLoS ONE. 6(10): e26836. 2011.
  • Okazaki N, Hazeki K, Izumi T, Nigorikawa K, and Hazeki O. C5a controls TLR-induced IL-10 and IL-12 production independent of phosphoinositide 3-kinase. J Biochem (Tokyo). 149: 265-274. 2011.
  • Sasai M, Oshiumi H, Funami K, Matsumoto M, and *Seya T. Direct binding of TRAF2 and TRAF6 to TICAM-1/TRIF adaptor participates in activation of the Toll-like receptor 3/4 pathway. Molec. Immunol. 47: 1283–1291. 2010.
  • Kubota N, Ebihara T, Matsumoto M, Gando S, and *Seya T. IL-6 and interferon-alpha from dsRNA-stimulated dendritic cells control expansion of regulatory T cells. Biochem. Biophys. Res. Commun. 391: 1421-1426. 2010.
  • Hirata N, Yanagawa Y, Satoh M, Ogura H, Ebihara T, Noguchi M, Matsumoto M, Togashi H, Seya T, Onoé K, and Iwabuchi K. Dendritic cell-derived TNF- is responsible for development of IL-10-producing CD4+ T cells. Cell. Immunol. 261: 37-41. 2010.
  • Oshiumi H, Sakai K, Matsumoto M, and *Seya T. DEAD/H BOX 3 (DDX3) helicase binds the RIG-I adaptor IPS-1 to up-regulate IFN-beta inducing potential. Eur. J. Immunol. 40: 940-948. 2010.
  • Akazawa T, Inoue N, Shime H, Sugiura K, Kodama K, Matsumoto M, and Seya T. Adjuvant engineering for cancer immunotherapy: development of a synthetic TLR2 ligand with increased cell adhesion. Cancer Sci. 101: 1596-1603. 2010.
  • Kasamatsu J, Oshiumi H, Matsumoto M, Kasahara M, and *Seya T. Phylogenetic and expression analysis of Lamprey Toll-like receptors. Dev. Comp. Immunol. 34: 855-865. 2010.
  • Azuma M, Sawahata R, Akao Y, Ebihara T, Yamazaki S, Matsumoto M, Hashimoto M, Fukase K, Fujimoto Y, and *Seya T. The peptide sequence of diacyl lipopeptides determines dendritic cell TLR2-mediated NK activation. PLoS ONE 5: e12550. 2010.
  • Tatematsu M, Ishii A, Oshiumi H, Horiuchi M, Inagaki F, Seya T, and Matsumoto M. A molecular mechanism for Toll/IL-1 receptor domain-containing adaptor molecule-1 (TICAM-1)-mediated IRF-3 activation. J. Biol. Chem. 285: 20128-20136. 2010.
  • Ebihara T, Azuma M, Oshiumi H, Kasamatsu J, Iwabuchi K, Matsumoto K, Saito H, Taniguchi T, Matsumoto M, and *Seya T. Identification of a polyI:C-inducible membrane protein, that participates in dendritic cell-mediated natural killer cell activation. J. Exp. Med. 207: 2675-2687. 2010.
  • Ehira N, Oshiumi H, Matsumoto M, Kondo T, Asaka M and Seya T. An embryo-specific expressing TGF-beta family protein, growth-differentiation factor 3 (GDF3), augments progression of B16 melanoma. J. Exp. Clin. Cancer Res. 29: 135. 2010.
  • Oshiumi H, Mori H, Ikeda M, Kato N, Matsumoto M, Takeuchi O, Akira S, Shimotohno K, and *Seya T. Hepatitis C virus (HCV) core protein abrogates the DDX3 function that enhances IPS-1-mediated IFN-beta induction. PLoS ONE. 5: e14258. 2010.
  • Oshiumi, H., M. Miyashita, N. Inoue, M. Okabe, M. Matsumoto, and T. Seya. Essential role of Riplet in RIG-I-dependent antiviral innate immune responses. Cell Host Microbe. 8: 496-509. 2010.
  • *Seya T, Matsumoto M, Shime H, Azuma M, and Oshiumi H. Innate immunity in progression from premalignant to malignant cells during inflammatory milieu. Cancer Sci. (submitted). 2015.
  • *Seya T. To the way from the knowledge on immunity and inflammation to immunotherapy against cancer. “Inflammation and Immunity in Cancer” Ed. by Seya T., Springer Press. (in press). 2015.(査読無)
  • Shime H, Matsumoto M,and Seya T. Regulation of tumor-associated myeloid cells by innate immune signaling. “Inflammation and Immunity in Cancer” Ed. by Seya T., Springer Press. (in press). 2015.(査読無)
  • Matsumoto M, Azuma M, and *Seya T. Adjuvant Immunotherapy for cancer: Basic research to clinical bench. “Inflammation and Immunity in Cancer” Ed. by Seya T., Springer Press. (in press). 2015.(査読無)
  • Takaki H, Oshiumi H, Matsumoto M, and *Seya T. Pattern recognition receptors for type I IFN induction in dendritic cell subsets in mouse models for measles virus infection. Int J Biochem Cell Biol. 53C: 329-333. 2014.
  • Tatematsu M, Seya T, and Matsumoto M. Beyond double-stranded RNA: TLR3 signaling in RNA-induced immune responses. Biochem. J. 458: 195-201. 2014.
  • *Seya T. Measles virus takes a two-pronged attack on PP1. Cell Host Microbe. 16: 1-2. 2014.
  • Matsumoto M, Funami K, Tatematsu M, Azuma M, and Seya T. Assessment of the Toll-like receptor 3 pathway in endosomal signaling. Methods. Enzymol. 535: 149-165. 2014.
  • Matsumoto M, Funami K, Oshiumi H, and Seya T. Toll-IL-1-receptor-containing adaptor molecule-1 (TICAM-1), a signaling adaptor linking innate immunity to adaptive immunity. “Oligomerization in health and diseases” ed. by J. Giraldo. Elsevier Inc. 2013.(査読無)
  • Kasamatsu J. Innate and adaptive pathogen recognition receptors in jawless vertebrates. Microbiol. Immunol. 57: 1-12. 2013.
  • Oshiumi H, Aly HH, Azuma M, Matsumoto M, and *Seya T. Multi-step regulation of interferon induction by hepatitis C virus. Arch Immunol Ther Exp. 61: 127-138. 2013.
  • *Seya T, Azuma M, and Matsumoto M. Targeting TLR3 with no RIG-I/MDA5 activation is effective in immunotherapy for cancer. Exp Opn Ther Targets. 17: 533-544. 2013.
  • Matsumoto, M., K. Funami, H. Oshiumi, and T. Seya. Toll-IL-1-receptor-containing adaptor molecule-1: a signaling adaptor linking innate immunity to adaptive immunity. Prog Mol Biol Transl Sci. 117: 487-510. 2013.
  • Oshiumi H, Matsumoto M, and Seya T. Ubiquitin-mediated modulation of the cytoplasmic viral RNA sensor RIG-I. J. Biochem (Tokyo). 151: 5-11. 2012.
  • Aly HH, Shimotohno K, Hijikata M, and Seya T. In vitro models for the analysis of HCV life cycle. Microbiol. Immunol. 56: 1-9 (doi: 10.1111). 2012.
  • *Seya T, Shime H, and Matsumoto M. TAMable tumor-associated macrophages in response to innate RNA sensing. OncoImmunol. 1: 1000-1001. 2012.
  • *Seya T, Shime H, Takaki H, Oshiumi H, and Matsumoto M. TLR3/TICAM-1 signaling in RIP3 tumor necroptosis. OncoImmunol. 1: 917-923. 2012.
  • Horiuchi T, Ohi H, Ohsawa I, Fujita T, Matsushita M, Okada N, Seya T, Yamamoto T, Endo Y, Hatanaka M, Wakamiya N, Mizuno M, Nakao M, Okada H, Tsukamoto H,  Inoue N, Nonaka M, and Kinoshita T. Guideline for hereditary angioedema (HAE) 2010 by the Japanese Association for Complement Research – secondary publication. Allergol Int. 61(4): 559-562. 2012.
  • *Seya T, and Miyake K. Toll-like receptor. Encyclopedia of Life Sciences Ed. by T. E. Creighton. John Wiley & Sons, Inc. New York, NY a0004028. www.els.net. 2012.(査読無)
  • Matsumoto M, Oshiumi H, and Seya T. Antiviral responses induced by the TLR3 pathway. Rev. Med. Virol. 21: 67–77 (review). 2011.
  • *Seya T, Kasamatsu J, Azuma M, Shime H, and Matsumoto M. Natural killer cell activation secondary to innate pattern sensing. J. Innate Immunity. 3: 264-273. 2011.
  • Wakita T, Suzuki T, Evans MJ, Shimotohno K, Chayama K, Matsuura Y, Hijikata M, Moriishi K, Seya T, Enomoto N, Koike K, Kato N, Kanto T, and Hotta H. Will there be an HCV meeting in 2020?: Summary of the 17th International Meeting on Hepatitis C Virus and Related Viruses. Gastroenterology 141: e1-5. 2011.
  • *Seya T, Shime H, Ebihara T, Oshiumi H, and Matsumoto M. Pattern-recognition receptors of innate immunity and their application to tumor immunotherapy. Cancer Sci. 101: 313-320 (review). 2010.
  • *Seya T, Innate immunity and vaccine. Vaccine 28: 8041-8042. (preface) 2010.

このページの先頭へ

【秋吉班】

  • Fujii H, Shin-Ya M, Takeda S, Hashimoto Y, Mukai S, Sawada S, Adachi T, *Akiyoshi K, Miki T, *Mazda O. Cancer Science, in press 2014.
  • Muraoka D, *Harada N, Hayashi T, Tahara Y, Momose F, Sawada S, Mukai S, Akiyoshi K, *Shiku H. A Nanogel-based Immunologically Stealth Vaccine Targets Macrophages in the Medulla of Lymph Node and Induces Potent Anti-Tumor Immunity, ACSNANO, in press 2014.
  • Takahashi H, Sawada S, *Akiyoshi K, Cationic amphiphilic polysaccharide nanoballs: protein stabilization and intracellular delivery by nanoencapsulation, Biomaterials Science, 1, 842–849, 2013.
  • Morimoto N, Yamazaki M, Tamada J,*Akiyoshi K.Polysaccharide-hair cationic polypeptide nanogels: Self-assembly and enzymatic polymerization of amylose primer modified cholesteryl poly(L-lysine), Langmuir, 29, 7509-7514, 2013.
  • Tahara Y, Kosuge S, Sawada S,*Akiyoshi K. Nanogel bottom-up gel biomaterials for protein delivery: photopolymerization of an acryloyl-modified polysaccharide nanogel macromonomer, Reactive and Functional Polymers, 73, 958-964, 2013.
  • Morimoto N, Hirano S, Takahashi H, Loethen S, Thompson DH, *Akiyoshi K.Self-assembled pH sensitive cholesteryl pullulan nanogel as a protein delivery vehicle Biomacromolecules, 14, 56-63, 2013.
  • Kong I, Sato A, Yuki Y, Nochi T, Takahashi H, Sawada S, Mejima M, Kurokawa S, Okada K, Sato S, Briles DE, Kunisawa J, Inoue Y, Akiyoshi K, *Kiyono H. Nanogel-Based PspA Intranasal Vaccine Prevents Invasive Disease and Nasal Colonization by Streptococcus pneumoniae Infect. Immun. 81(5), 1625-1634, 2013.
  • Takeda S, Takahashi H, Sawada S, Sasaki Y, *Akiyoshi K. Amphiphilic nanogel of enzymatically synthesized glycogen as an artificial molecular chaperone for effective protein refolding, RSC Advances, 3, 25716-25718, 2013.
  • Sekine Y, Moritani Y, Ikeda-Fukazawa T, Sasaki Y, *Akiyoshi K. Hybrid hydrogel biomaterial by nanogel engineering: bottom-up design with nanogel and liposome building blocks to develop a multi-drug delivery system, Advance Healthcare Materials, 1(6), 722-728, 2012.
  • Shimoda A, Sawadad S, Kano A, Maruyama A, Moquin A, Winnik FM, *Akiyoshi K. Dual crosslinked hydrogel nanoparticles by nanogel bottom-up method for sustained-release delivery, Colloids and Surfaces B: Biointerfaces, 99, 38-44, 2012.
  • Shimoda A, Yamamoto Y, Sawada S, *Akiyoshi K. Biodegradable Nanogel-integrated Hydrogels for Sustained Protein Delivery, Macromolecular Research, 20, 266-270, 2012.
  • Y.Sasaki, *K. Akiyoshi, Self-assembled Nanogel Engineering for Advanced Biomedical Technology, Chem. Lett. 41, 202-208, 2012
  • H. Takahashi, S. Sawada, *K. Akiyoshi, Amphiphilic polysaccharide nanoballs: a new building block for nanogel biomedical engineering and artificial chaperone, ACS Nano. 5, 337-345, 2011.
  • Sasaki Y, Hirakura T, Sawada S, *Akiyoshi K. Metal coordinative-crosslinked polysaccharide nanogels with redox sensitivity, Chem. Lett., 40, 182-183, 2011.
  • Sawada S, Sasaki Y, Nomura Y, *Akiyoshi K. Cyclodextrin-responsive nanogel as an artificial chaperone for horseradish peroxidase, Colloid Polym. Sci., 289, 685–691. 2011.
  • Sasaki Y, Asayama W, Niwa T, Sawada S, Ueda T, Taguchi H, *Akiyoshi K, Amphiphilic Polysaccharide Nanogels as an Artificial Chaperone in Cell-Free Protein Synthesis, Macromol. Bioscience, 11, 814-820, 2011.
  • Sasaki Y, Tsuchido Y, Sawada S, *Akiyoshi K. Construction of protein-crosslinked nanogels with vitamin B6 bearing polysaccharide, Polym. Chem., 2, 1267-1270, 2011.
  • Shimoda A,Sawada S, *Akiyoshi K. Cell specific peptide-conjugated polysaccharide nanogels for protein delivery, Macromol. Bioscience, 11, 882-888, 2011.
  • Watanabe K, Tsuchiya Y, Kawaguchi Y, Sawada S, Ayame H, Akiyoshi K, *Tsubata T. Cationic nanogels efficiently deliver proteins to myeloma cells and primary T lymphocytes poorly expressing heparan sulfate, Biomaterials, 32, 5900-5905, 2011.
  • Toita S, Sawada S,*Akiyoshi K. Polysaccharide nanogel gene delivery system with endosome-escaping function: Co-delivery of plasmid DNA and phospholipase A2, J. Controlled Release, 155, 54-59, 2011.
  • Toita S, Morimoto N, *Akiyoshi K. Functional cycloamylose-based biomaterial: application in a gene delivery system, Biomacromolecules, 11, 397- 401,2010.
  • Sasaki Y,*Akiyoshi K. Development of an Artificial Chaperone System Based on Cyclodextrin, Current Pharmaceutical Biotechnology, 11, 300-305, 2010.
  • Nochi T, Yuki Y, Takahashi H, Sawada S, Mejima M, Kohda T, Harada N, Kong G, Sato A, Kataoka N, Tokuhara D, Kurokawa S, Takahashi Y, Tsukada H, Kozaki S, Akiyoshi K, *Kiyono H. Nanogel antigenic protein delivery system for adjuvant-free intranasal vaccines, Nature Materials, 9, 572-578 , 2010.
  • Shime H, Matsumoto M, Oshiumi H, Tanaka S, Nakane A, Iwakura Y, Tahara H, Inoue N, and *Seya T. TLR3/TICAM-1 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc Natl Acad Sci USA. 109: 2066-2071. 2012.

このページの先頭へ

公募班

主要1編のみの掲載です。

【渋谷班】

  • Totsuka N, Kim YG, Kanemaru K, Niizuma K, Umemoto E, Nagai K, Tahara-Hanaoka S, Nakahasi-Oda C, Honda S, Miyasaka M, Shibuya K, *Shibuya A. Toll-like receptor 4 and MAIR-II/CLM-4/LMIR2 immunoreceptor regulate VLA-4-mediated inflammatory monocyte migration. Nature Communication. 5:4710, 2014.

【深山班】

  • Nakaya T, Kikuchi Y, Kunita A, Ishikawa S, Matsusaka K, Hino R, Aburatani H, *Fukayama M. Enrichment of stem-like cell population comprises transformation ability of Epstein-Barr virus latent membrane protein 2A for non-transformed cells. Virus Res. 174:108-15, 2013.

【土屋班】

  • Nemoto Y, Kanai T, Takahara M, Oshima S, Nakamura T, Okamoto R, Tsuchiya K, *Watanabe M: Bonemarrow-mesenchymal stem cells are a major source of interleukin-7 and sustain colitis by forming the niche for colitogenic CD4+ memory T cells. Gut. 62: 1142-52, 2013.

【川上班】

  • Kono Y, *Kawakami S, Higuchi Y, Maruyama K, Yamashita F, *Hashida M. Antitumor effect of nuclear factor-κB decoy transfer by mannose-modified bubble lipoplex into macrophages in mouse malignant ascites. Cancer Sci. 105(8):1049-55, 2014.

【西川班】

  • *Nishikawa M, Ogawa K, Umeki Y, Mohri K, Kawasaki Y, Watanabe H, Takahashi N, Kusuki E, Takahashi R, Takahashi Y, Takakura Y. Injectable, self-gelling, biodegradable, and immunomodulatory DNA hydrogel for antigen delivery. J. Control. Release 180, 25-32 2014.

【金子班】

  • Iriguchi S, Kikuchi N, *Kaneko S, Noguchi E, Morishima Y, Matsuyama M, Yoh K, Takahashi S, Nakauchi H, *Ishii Y, T cell-restricted T-bet overexpression induces aberrant hematopoiesis of myeloid cells and impairs function of lung macrophages in the lung, Blood., in press 2014..

【田村班】

  • Suzuki H, Nishizawa T, Tani K, Yamazaki Y, Tamura A, Ishitani R, Dohmae N, Tsukita S, *Nureki O, *Fujiyoshi Y. Crystal structure of a claudin provides insight into the architecture of tight junctions. Science 2014, 344:304-307.

【小谷班】

  • Yamashita H, *Kotani T, Park J.H, Murata Y, Okazawa H, Ohnishi H, Ku Y, *Matozaki T. Role of the protein tyrosine phosphatase Shp2 in homeostasis of the intestinal epithelium. Plos One, 9, e92904, 2014.

【井垣班】

  • Nakamura M, Ohsawa S, *Igaki T. Mitochondrial defects trigger proliferation of neighbouring cells via a senescence-associated secretory phenotype in Drosophila. Nature Communications, in press 2014.

【岡田班】

  • Goto H, Kojima Y, Matsuda K, Kariya R, Taura M, Kuwahara K, Nagai H, Katano H, *Okada S. Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma. Eur J Cancer 50(10):1836-1846, 2014.

【小原班】

  • Arai M, Tokunaga Y, Takagia A, Tobita Y, Hirata Y, Ishida Y, Tateno C, *Kohara M. Isolation and characterization of highly replicable hepatitis C virus genotype 1a strain HCV-RMT. PLoSONE 8(12):e82527. doi: 10.1371/journal.pone.0082527, 2013.

このページの先頭へ

 

Copyright © 文部科学省科学研究費補助金新学術領域研究「感染・炎症が加速する発がんスパイラルとその遮断に向けた制がんベクトル変換」